Relay Therapeutics, Inc. (RLAY) - What Are Investment Firms Saying About This Stock?

Relay Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly positive: Fourteen brokerages give Relay Therapeutics a “Moderate Buy” consensus, with 11 buy and one strong-buy rating; the average 12-month price target is $27.
  • Recent analyst targets range from $26 to $31, including JonesTrading raising its target to $31. Shares opened at $17.27 and were reported down 4.5%.
  • Relay reported quarterly EPS of -$0.37, slightly better than the -$0.40 consensus estimate. Institutional investors and hedge funds own 96.98% of the stock.
  • MarketBeat previews top five stocks to own in December.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $27.00.

RLAY has been the topic of a number of research analyst reports. JonesTrading lifted their target price on Relay Therapeutics from $20.00 to $31.00 and gave the company a "buy" rating in a research report on Friday, November 6th. Citizens Jmp increased their price target on Relay Therapeutics from $21.00 to $26.00 and gave the stock a "market outperform" rating in a report on Monday, August 10th. Citigroup reiterated a "market outperform" rating on shares of Relay Therapeutics in a report on Monday, August 10th. HC Wainwright raised their price objective on Relay Therapeutics from $28.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Finally, Barclays boosted their price objective on shares of Relay Therapeutics from $27.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, August 7th.

Check Out Our Latest Stock Analysis on RLAY

Relay Therapeutics Trading Down 4.5%

Shares of RLAY stock opened at $17.27 on Tuesday. The company's 50-day moving average price is $18.34 and its 200-day moving average price is $15.53. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of -11.44 and a beta of 1.74. Relay Therapeutics has a twelve month low of $6.17 and a twelve month high of $21.27.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.03. As a group, equities research analysts predict that Relay Therapeutics will post -1.58 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Thomas Catinazzo sold 1,469 shares of the firm's stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $18.62, for a total value of $27,352.78. Following the completion of the transaction, the chief financial officer owned 103,665 shares of the company's stock, valued at approximately $1,930,242.30. This trade represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Donald Bergstrom sold 2,252 shares of Relay Therapeutics stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $18.62, for a total transaction of $41,932.24. Following the completion of the transaction, the insider owned 396,878 shares of the company's stock, valued at $7,389,868.36. This trade represents a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 6,149,344 shares of company stock valued at $119,185,625. Insiders own 5.04% of the company's stock.

Institutional Trading of Relay Therapeutics

Several hedge funds have recently modified their holdings of RLAY. BlackRock Inc. acquired a new stake in shares of Relay Therapeutics in the 2nd quarter valued at $286,042,000. Perceptive Advisors LLC lifted its position in shares of Relay Therapeutics by 412.3% during the 1st quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company's stock worth $97,024,000 after purchasing an additional 7,847,896 shares during the last quarter. Spruce Street Capital LP purchased a new stake in shares of Relay Therapeutics during the 2nd quarter worth $55,832,979. Bank of America Corp DE acquired a new position in shares of Relay Therapeutics during the second quarter worth $50,425,000. Finally, EcoR1 Capital LLC acquired a new position in shares of Relay Therapeutics during the first quarter worth $18,952,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay's research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.

Recommended Stories

Analyst Recommendations for Relay Therapeutics (NASDAQ:RLAY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Relay Therapeutics Right Now?

Before you consider Relay Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.

While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines